🇨🇦 |Radiation Oncologist @RadMedPM @PMcancercentre @UofTdro | Alumnus @Sunnybrook @QueensOncology @JohnsHopkinsSPH @SchulichMedDent | Views = mine
Toronto, Ontario
Joined January 2012
- Tweets272
- Following465
- Followers416
- Likes1.5K
Michael Yan, MD MPH retweeted
Enjoyed this session & learned a lot!
Both TARE & SBRT can deliver ablative RT in HCC. Key q is which approach is best suited for a given pt/tumor.
Sharing some of my slides below re: decision-making b/w the 2 modalities.
TY to @GIcancerDoc & @EileenMOReilly for the invite.
Michael Yan, MD MPH retweeted
⚡️Thrilled and proud are words that just do not do justice to getting to work with our @RadOncUH team & collaborators to help bring #Accela to (pre-)clinical life, first in the world on the SPEED clinical trial this August, thanks to tireless efforts by @APrice_BeamOn @Betyguevarasoto @DrSpratticus @angela_jia_ @KashaniRojano and countless others with our partners @SiemensHealth and academic partners at @WashUMedRadOnc @MayoRadOnc @MSK_RadOnc @MGBResearchNews @RadOncUSZ and @MAASTROclinic
#ASTRO26
@lauren_henke from @RadOncUH showing the data from the very first patients in the world on the SPEED trial using Varians new Accela unit.
@ASTRO_org @ASCO @NRGonc @NehaVapiwala @HimanshuNagarMD @AmarUKishan @APrice_BeamOn @angela_jia_ @KashaniRojano @PranshuMohindra @Soum_Roy_RadOnc @HaleyPerlow @DrewMoghanaki @MayoClinic @MSKCancerCenter
Michael Yan, MD MPH retweeted
Radiotherapy after surgery halves risk of recurrence in a type of brain tumour that can often grow back, trial shows.
Find out more in The Lancet: spkl.io/60137TUFS #EANO2026
ALT Kaplan\u2013Meier estimates of disease-free survival by treatment group in the intention-to-treat population. Median follow-up was 64 months (IQR 50\u201375). HR=hazard ratio. Copyright: 2026 The Author(s). Published by Elsevier Ltd. CC BY 4.0.
Michael Yan, MD MPH retweeted
Microwave ablation versus stereotactic body radiotherapy for oligometastatic colorectal liver metastases (LAVA-CRLM): a prospective, randomised, phase II trial
thelancet.com/journals/lanep…
Michael Yan, MD MPH retweeted
Really useful app for estimating OAR cumulative dose & dose reserve for re-irradiation planning by @jryckman3!
We are going to record a video going through some case examples.
Let us know if any specific qs.
radonc.org/reirradiation
ReRT planning is hard.
So we built a free EQD2-based D0.1cc calculator to help estimate remaining OAR reserve across prior RT courses, with both no-forgiveness and time-forgiveness options.
Decision support only. Use judgment. Verify independently.
#RadOnc #OncTwitter
Michael Yan, MD MPH retweeted
So thrilled to see our collaborative publication with @tedradonc, @ma5RN and many others now online in @JCO_ASCO
These data from a large, multinational cohort provide further support for EBRT's role in the management of HCC.
ascopubs.org/doi/10.1200/JCO…
Michael Yan, MD MPH retweeted
Thank you @TheLancetOncol for accepting the concurrent publication of the data…. To read more see QR code here; #ESTRO26 #radonc
Michael Yan, MD MPH retweeted
Ablative RT often causes tissue changes within a few mm outside of the target lesion
Can give the appearance of tumor "growth" when this often is pseudoprogression
CT/MRI reports often do not reflect this possibility
Larger size does not always mean local failure!!
Michael Yan, MD MPH retweeted
The entire @Sunnybrook spine #SBRT team has come together to share 17 years of research and clinical observations in this review for @NatRevClinOncol. We are a true multidisciplinary team that have had a singular focus to develop the technique and evidence nature.com/articles/s41571-0…
Michael Yan, MD MPH retweeted
1/7 🧵 New in @LancetOncology: we built a Delphi consensus on primary endpoints for MDT trials in oligometastatic cancer — because the endpoints we've been using were designed for drugs, not for ablation.
On behalf of the EORTC–ESTRO OligoCare consortium.
Michael Yan, MD MPH retweeted
Wow. Thank you everyone for such an amazing response to this article. 60K views in 24 hrs for an academic article in the current era of X is truly encouraging. Speaks to the “unmet need” of educational resources for critical appraisal. ascopubs.org/doi/10.1200/OP-…
How I Read a Clinical Trial Report? A Primer for Busy Clinicians | JCO Oncology Practice
ascopubs.org
A MUST-READ!
This is probably one of my most important papers where I try to teach how to fish rather than offer fish.
How I Read a Clinical Trial Report?
BG’s primer for Busy Clinicians.
Thank you @JCOOP_ASCO @EthicsdoctorP for the kind invitation. I hope the readers will find this useful.
ascopubs.org/doi/10.1200/OP-…
Michael Yan, MD MPH retweeted
Check out our amazing meta analysis FIRE-STORM, showing PFS significantly better with DE-RT over 66 Gy in 33 for high grade meningioma. We hope this will help as we prepare to show for over 70 Gy improves control in future trial!!
redjournal.org/article/S0360…
Michael Yan, MD MPH retweeted
Barcelona HCC classification may not reflect current treatment practices in US
The new BEACON-HCC Classification was introduced for comment today @HCCLIVEConf - pls weigh in!
Pilot real-world cases: Expert concordance 100% with BEACON-HCC vs 58.6% with 2022 #BCLC
Michael Yan, MD MPH retweeted
#HRQOL #oligoprog #SBRT
🔥RADIANT - phII oligoprog GI, GU, breast
🔵 secondary outcome - HRQOL
⬇️ mean global health SS but not clinically significant at 6m
🔵disease progression predictor of worse HRQOL on MVA
🔵if no prog HRQOL was stable or improved in 83%
1/
Michael Yan, MD MPH retweeted
𖠣 New in @TheJNS Spine: Does timing matter? Analysis led by @MichaelYanMD @UHN found improved locoregional cancer control among patients who receive radiotherapy before vertebral augmentation for spine metastases: tinyurl.com/3k9ckx32 @UofTDRO @UofTNeuroSurge @UofTMedIm
Michael Yan, MD MPH retweeted
First prospective series to demonstrate #SBRT could induce contralateral lobe hypertrophy in #HCC
- Around 30% increase in FLR
- Fastest rate in first 3 months
- Ongoing hypertrophy until plateauing at 12 months
Full text link: redjournal.org/article/S0360…
Michael Yan, MD MPH retweeted
Excellent outcomes from HK following SBRT-IO for HCC (73% MVI, med. 11cm).
Strong rationale for phase 3 RCTs. Please support #NRG GI012 IO+\- SBRT for HCC w MVI.
Michael Yan, MD MPH retweeted
Long-term results of Ph2 celiac plexus SRS trial (n=107)
1 dose RT (25Gy) led to 60% pain reduction & pain control for 4+ mo.
Suggestion of better durability when tumor included (w plexus) in RT volume.
RCT in development. Great work Yaacov Lawrence & team! #GI26 @OncoAlert
Michael Yan, MD MPH retweeted
Advanced cirrhosis (CP-B8/C) often precludes embolic bridging (Y90/TACE) in HCC, so options limited.
Small, uniquely targeted pilot study suggests SBRT could fill gap: local control 100% (40Gy/5fx), & 67% transplanted or eligible after 1 yr. @OncoAlert
redjournal.org/article/S0360…
Absolute pleasure hosting @lauren_henke @APrice_BeamOn and learning from world leaders in adaptive RT. Innovative as always, and inspiration to leverage tech to move the needle and improve patient outcomes. – at Toronto, Ontario
Wonderful to get to visit friends @RadMedPM 🇨🇦 + rep @RadOncUH w/ @APrice_BeamOn 💪🏼Hard to beat company like @ldawsonmd @j_lukovic @MichaelYanMD et al, getting to be part of their annual GI SBRT course, & even getting to talk about pancreas RT on World Pancreatic Cancer Day 💜 Thanks for having us! @caseccc @UH_RE_Institute
